Scarica l'app Stockscreener
53.48
6.60%
3.31
Dopo l'orario di chiusura:
53.55
0.07
+0.13%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GPCR Giù?
Forum
Previsione
Structure Therapeutics Inc Adr Borsa (GPCR) Ultime notizie
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Why Structure Therapeutics Stock Is Suddenly Surging - TipRanks
Structure Therapeutics (NASDAQ:GPCR) Stock Price Up 10.8%What's Next? - MarketBeat
LLY Stock Up on GLP-1 Pill Approval: Can it Outpace NVO's Wegovy Pill? - TradingView
Exchange Traded Concepts LLC Sells 32,241 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Lilly gains after FDA approves weight-loss pill, sizing down investor doubts - Sahm
Structure Therapeutics Stock Jumps on Obesity Drug Buzz - TipRanks
Structure Therapeutics Shares Surge on Obesity Drug Breakthrough - TipRanks
Structure Therapeutics (GPCR) Is Down 5.5% After Strong Oral GLP-1 Phase 2 DataWhat's Changed - Sahm
Structure Therapeutics (NASDAQ:GPCR) Stock Rating Lowered by Wall Street Zen - MarketBeat
Structure Therapeutics Obesity Trial Success Puts Valuation Gap In Focus - Sahm
Structure Therapeutics (NASDAQ:GPCR) Coverage Initiated by Analysts at Wolfe Research - MarketBeat
Wolfe Research initiates Structure Therapeutics stock rating at Peerperform By Investing.com - Investing.com India
Wolfe Research initiates Structure Therapeutics stock rating at Peerperform - Investing.com
GPCR SEC FilingsStructure Therapeutics Inc ADR 10-K, 10-Q, 8-K Forms - Stock Titan
Structure Therapeutics (NASDAQ: GPCR) awards new options and RSUs - Stock Titan
Structure Therapeutics (GPCR) CMO receives new stock options and RSU grants - Stock Titan
Structure Therapeutics (GPCR) CTO awarded options and 32,526 RSUs - Stock Titan
Structure Therapeutics (GPCR) grants CSO new stock options and RSUs - Stock Titan
Structure Therapeutics (GPCR) CFO receives large option and RSU grants - Stock Titan
Structure Therapeutics (NASDAQ: GPCR) CEO awarded new options and 260,217 RSUs - Stock Titan
NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now? - Yahoo Finance
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges - AOL.com
B Group Acquires 4.62% Portfolio Stake in Structure Therapeutics | 2025 InvestmentNews and Statistics - IndexBox
LifeSci Capital Keeps Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Scholar Rock Holding (SRRK), Summit Therapeutics (SMMT) - theglobeandmail.com
Experience real-time quotes, in-depth charts, and analyst ratings - webull.com
Did Positive Phase 2 Aleniglipron Data Just Shift Structure Therapeutics' (GPCR) Investment Narrative? - Sahm
How (GPCR) Movements Inform Risk Allocation Models - Stock Traders Daily
Structure Therapeutics (NASDAQ:GPCR) Shares Down 7.5%Should You Sell? - MarketBeat
Why Structure Therapeutics Shares Are Tumbling Today - TipRanks
Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and Lifecore Biomedical (LFCR) - The Globe and Mail
What is HC Wainwright's Forecast for GPCR FY2027 Earnings? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), Voyager Therapeutics (VYGR) and Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Lantheus (LNTH), Perspective Therapeutics (CATX) - The Globe and Mail
Structure Therapeutics Posts 15%+ Weight Loss in ACCESS II for Oral GLP-1 Aleniglipron, Eyes Phase III - MarketBeat
Buy Rating on GPCR Driven by Competitive Aleniglipron Phase 2b Efficacy and Clear Path to Phase 3 in Obesity - TipRanks
Analysts Are Bullish on Top Healthcare Stocks: HeartBeam (BEAT), Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
H.C. Wainwright lowers Structure Therapeutics price target on penetration assumptions - Investing.com
Citizens reiterates Structure Therapeutics stock rating on weight loss data - Investing.com
Structure Therapeutics Oral GLP-1 Obesity Drug Achieves ‘Injectable-Like Efficacy’ in Phase 2 Test - MedCity News
Structure Therapeutics’ Stock Climbing Amid 44-Week Trial Data Buzz - StocksToTrade
William Blair reiterates Structure Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
Structure Therapeutics (NASDAQ:GPCR) Sees Strong Trading VolumeStill a Buy? - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Given New $100.00 Price Target at HC Wainwright - MarketBeat
Structure Therapeutics ADR receives Investment Bank Analyst Rating Update By Investing.com - Investing.com Canada
Structure Therapeutics (GPCR) Stock Surges 10% as GLP-1 Pill Outperforms Lilly and Novo - CoinCentral
Leerink reiterates Outperform on Structure Therapeutics stock - Investing.com
Structure Therapeutics Reports Strong Phase 2 Obesity Drug Results - TipRanks
Structure Therapeutics Inc Reports Positive Topline Data From Phase 2 ACCESS II Trial With Once-Daily Oral Small Molecule GLP-1 Receptor Agonist Aleniglipron - marketscreener.com
Structure Therapeutics (NASDAQ: GPCR) shows 16% weight loss in Phase 2 oral GLP-1 trial - Stock Titan
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron - Bitget
Why Structure Therapeutics Shares Are Sliding Today - TipRanks
HighVista Strategies LLC Acquires 149,615 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):